Semaglutide has been studied across the SUSTAIN and STEP trial programmes, establishing robust evidence in both type 2 diabetes and obesity without diabetes populations
They do not provide product-use, preparation, administration, dosing, injection, clinical or treatment guidance
Therefore, the combined use of GLP-1 RAs with therapies targeting intrahepatic pathways, such as thyroid hormone receptor (THR-) agonists, fibroblast growth factor-21 (FGF21) analogues, and peroxisome proliferator-activated receptor (PPAR) agonists, presents a promising approach for MASH treatment
This makes it difficult for you and us to know the right dose for you
This suits people focused on maintaining progress rather than pushing for further weight loss